Literature DB >> 12737278

Impact of pain in a Dutch sarcoidosis patient population.

Elske Hoitsma1, Jolanda De Vries, Marijke van Santen-Hoeufft, Carin G Faber, Marjolein Drent.   

Abstract

BACKGROUND AND AIM: Although pain is prevalent in sarcoidosis, this has never been studied systematically. The aim of the present study was to evaluate the presence and impact of pain in sarcoidosis.
METHODS: Members from the Dutch Sarcoidosis Society without co-morbidity (n = 821) participated in this study. The World Health Organisation Quality of Life assessment instrument (WHOQOL-100) was completed, as well as a symptom inventory questionnaire addressing the presence of various categories of pain, i.e., muscle pain, chest pain, abdominal pain, arthralgia, and/or headache.
RESULTS: Pain was reported by 594 patients (72.4%). Arthralgia was experienced most frequently (53.8%), followed by muscle pain (40.2%), headache (28.0%) and chest pain (26.9%). The number of types of pain a patient was suffering from (ranging from 0-5) was related to the WHOQOL- 100 Pain and Discomfort scale (r = 0.49, p < 0.001). Patients with more types of pain had lower quality of life (QOL). In addition, the total amount of experienced pain categories was associated with the WHOQOL-100 domain Level of Independence (r = -O.43, p < 0.001), and the facet Energy and Fatigue (r = -0.38, p < 0.001). The number of types of pain was predicted by using analgesics, psychological/neurological medication, NSAIDs, being female, indicating to feel tired, more negative feelings and less energy (F(7.635) = 35.2, p < 0.001; R2 = 27.9%).
CONCLUSIONS: Pain appeared to be a major problem in sarcoidosis, especially arthralgia. Although negative feelings and fatigue were related to pain, it could not fully explain pain. Future studies are needed to address mechanisms of pain, pain behaviour, and the best therapeutic approach to pain in sarcoidosis.

Entities:  

Mesh:

Year:  2003        PMID: 12737278

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   0.670


  9 in total

Review 1.  Patient reported outcome measures (PROMs) in sarcoidosis.

Authors:  Rikke Flor Thunold; Anders Løkke; Adam Langballe Cohen; Hilberg Ole; Elisabeth Bendstrup
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

Review 2.  The Clinical Features of Sarcoidosis: A Comprehensive Review.

Authors:  Marc A Judson
Journal:  Clin Rev Allergy Immunol       Date:  2015-08       Impact factor: 8.667

Review 3.  Sarcoidosis and small-fiber neuropathy.

Authors:  Jinny Tavee; Daniel Culver
Journal:  Curr Pain Headache Rep       Date:  2011-06

4.  Pain and autonomic dysfunction in patients with sarcoidosis and small fibre neuropathy.

Authors:  M Bakkers; C G Faber; M Drent; M C E Hermans; S I van Nes; G Lauria; M De Baets; I S J Merkies
Journal:  J Neurol       Date:  2010-07-20       Impact factor: 4.849

5.  ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density.

Authors:  Albert Dahan; Ann Dunne; Maarten Swartjes; Paolo L Proto; Lara Heij; Oscar Vogels; Monique van Velzen; Elise Sarton; Marieke Niesters; Martijn R Tannemaat; Anthony Cerami; Michael Brines
Journal:  Mol Med       Date:  2013-11-08       Impact factor: 6.354

Review 6.  Management of neurosarcoidosis: a clinical challenge.

Authors:  Mareye Voortman; Marjolein Drent; Robert P Baughman
Journal:  Curr Opin Neurol       Date:  2019-06       Impact factor: 5.710

7.  The Burden of Sarcoidosis Symptoms from a Patient Perspective.

Authors:  M Voortman; C M R Hendriks; M D P Elfferich; F Bonella; J Møller; J De Vries; U Costabel; M Drent
Journal:  Lung       Date:  2019-02-16       Impact factor: 2.584

8.  Case Report: Pulmonary and Liver Sarcoidosis Suspected of Metastasis.

Authors:  Behnam Jafari; Gholamabas Sabz; Elahe Masnavi; Roghaye Panahi; Saeid Jokar; Amrollah Roozbehi; Sajad Hasanzadeh
Journal:  F1000Res       Date:  2018-03-07

Review 9.  Developing better drugs for pulmonary sarcoidosis: determining indications for treatment and endpoints to assess therapy based on patient and clinician concerns.

Authors:  Marc A Judson
Journal:  F1000Res       Date:  2019-12-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.